Neurent Medical, the company behind NEUROMARK, a minimally invasive solution to treat chronic rhinitis, today announced the successful close of its oversubscribed Series C financing, raising €62.5 million ($74 million) to drive commercial expansion, broaden clinical evidence, and advance its product and indication pipeline.
Chronic rhinitis affects millions of people worldwide and is characterized by persistent symptoms including nasal congestion, rhinorrhea (runny nose), sneezing and postnasal drip that can significantly diminish quality of life. NEUROMARK's proprietary Impedance Controlled Radiofrequency technology targets the overactive posterior nasal nerves (PNN) that drive these symptoms, providing clinicians with a durable treatment option designed to address the root cause.
Headquartered in Galway, Ireland, with U.S. operations in Braintree, Massachusetts, Neurent is advancing both scientific evidence and clinical adoption to establish a new standard of care in chronic rhinitis management.
